Home Cart Sign in  
Chemical Structure| 10356-76-0 Chemical Structure| 10356-76-0

Structure of 5-Fluoro-2'-deoxycytidine
CAS No.: 10356-76-0

Chemical Structure| 10356-76-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

5−Fluoro−2'−deoxycytidine is a DNMT inhibitor which forms covalent links with the cysteine residue in the DNMT active site.

Synonyms: 2'-Deoxy-5-Fluorocytidine; FCdR; FdCyd

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of 5-Fluoro-2'-deoxycytidine

CAS No. :10356-76-0
Formula : C9H12FN3O4
M.W : 245.21
SMILES Code : O=C1N=C(N)C(F)=CN1[C@@H]2O[C@H](CO)[C@@H](O)C2
Synonyms :
2'-Deoxy-5-Fluorocytidine; FCdR; FdCyd
MDL No. :MFCD00077348
InChI Key :IDYKCXHJJGMAEV-RRKCRQDMSA-N
Pubchem ID :515328

Safety of 5-Fluoro-2'-deoxycytidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Related Pathways of 5-Fluoro-2'-deoxycytidine

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
KYSE150 1 μM 72 h FCdR inhibited KYSE150 cell proliferation with a survival rate of about 30%. Springerplus. 2012 Dec;1(1):65
U2OS 1 μM 72 h FCdR inhibited U2OS cell proliferation with a survival rate of about 80%. Springerplus. 2012 Dec;1(1):65
HEPG2 1 μM 72 h FCdR inhibited HEPG2 cell proliferation with a survival rate of about 40%. Springerplus. 2012 Dec;1(1):65
dCMPD-/TK- double mutant S-49 cells 1 μM Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking both dCMP deaminase and thymidine kinase, showing significantly reduced toxicity. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
dCMPD- mutant S-49 cells 3 nM Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking dCMP deaminase, showing reduced toxicity. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
dCK- mutant S-49 cells 20 nM Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking deoxycytidine kinase, showing reduced toxicity. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
TK- mutant S-49 cells 10 nM Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cells lacking thymidine kinase, showing reduced toxicity. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
S49 mouse lymphoma cells 2 nM Evaluate the inhibitory effect of 5-Fluoro-2'-deoxycytidine on cell growth, showing it primarily acts by inhibiting thymidylate synthetase. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6419-23
Caki-1 PBRM1-/- 10uM 72 h To screen for synthetic lethal drugs in PBRM1-deficient renal cancer cells Front Oncol. 2022 Jun 3;12:870229
Caki-1 PBRM1+/+ 10uM 72 h To screen for synthetic lethal drugs in PBRM1-deficient renal cancer cells Front Oncol. 2022 Jun 3;12:870229
Human ependymoma PDX 8.3 nM 72 h To evaluate the inhibitory effect of FdCyd on human ependymoma PDX cell proliferation, showing an EC50 of 8.3 nM. J Neurooncol. 2016 Jan;126(2):225-34
Human G3 medulloblastoma PDX (TB-12-5950) 1 nM 72 h To evaluate the inhibitory effect of FdCyd on human G3 medulloblastoma PDX cell proliferation, showing an EC50 of 1 nM. J Neurooncol. 2016 Jan;126(2):225-34
Mouse choroid plexus carcinoma (CPC) 5.6 nM 72 h To evaluate the inhibitory effect of FdCyd on choroid plexus carcinoma cell proliferation, showing an EC50 of 5.6 nM. J Neurooncol. 2016 Jan;126(2):225-34
Mouse ependymoma (EP) 4 nM 72 h To evaluate the inhibitory effect of FdCyd on ependymoma cell proliferation, showing an EC50 of 4 nM. J Neurooncol. 2016 Jan;126(2):225-34
Mouse G3 medulloblastoma (Myc1) 1.7 nM 72 h To evaluate the inhibitory effect of FdCyd on G3 medulloblastoma cell proliferation, showing an EC50 of 1.7 nM. J Neurooncol. 2016 Jan;126(2):225-34

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
CD1 nude mice G3 medulloblastoma, ependymoma, and choroid plexus carcinoma models Intravenous injection 6 mg/kg 5 days treatment followed by 2 days off for 2 weeks for a 4-week cycle To evaluate the in vivo efficacy of FdCyd and THU combination therapy in G3 medulloblastoma, ependymoma, and choroid plexus carcinoma models, showing no significant tumor growth inhibition. J Neurooncol. 2016 Jan;126(2):225-34
BALB/c nude mice 786-O PBRM1+/+ and PBRM1-/-#1 xenograft model Oral 25mg/kg Daily for 21 days To evaluate the synthetic lethal effect of Fdcyd in PBRM1-deficient renal cancer Front Oncol. 2022 Jun 3;12:870229

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.08mL

0.82mL

0.41mL

20.39mL

4.08mL

2.04mL

40.78mL

8.16mL

4.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories